Trial Profile
A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2024
Price :
$35
*
At a glance
- Drugs Diazepam (Primary) ; Benzodiazepines
- Indications Epilepsy; Generalised epilepsy; Partial epilepsies; Seizures
- Focus Registrational; Therapeutic Use
- Sponsors Neurelis
- 04 Jan 2024 Results of exploratory Post Hoc analysis assessing effect of timing of rescue therapy administration for seizure clusters in epilepsy , published in the Neurology and Therapy
- 01 Dec 2023 Results presented in a Neurelis Media Release.
- 01 Dec 2023 According to a Neurelis Media Release, post-hoc analysis data from this study will present six poster presentations at the American Epilepsy Society (AES) Annual Meeting held in Orlando, Florida from December 1-5, 2023.